🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Getting ready for #ASCO23 opening session and making time to connect with friends and colleagues like ASCO CEO @cliffordhudis. Hope you’ll join me this morning as I discuss the importance of partnering with patients.

The question is what have I learned from this chronicle that could be helpful to all of you, and more specifically, how does my experience contribute to our collective understanding of partnerships between patients and clinicians in oncology? I have some thoughts.... 1/4 #ASCO23

“I hope to be one of those people with cancer who live a full and active life free from cancer’s harmful effects. What has given me this hope? Science. Research. All that we celebrate at each ASCO Annual Meeting.” -Dr. Kimryn Rathmell #ASCO23 #NationalCancerSurvivorsMonth

Thrilled to be back at #ASCO23 in person for the first time in 4 years. Congrats & thank you Eric J. Small, MD, FASCO, Kimmie Ng, MD, MPH and the whole ASCO team on a fantastic meeting. Great to see so many friends and colleagues in person for the first time in ages. Need to do this again soon!

Congrats to Nayan Lamba, MD on a fantastic oral presentation on her study of genomic alterations associated w brain met response to radiotherapy. Findings could help identify patients who benefit most from radiation. Thx to Conquer Cancer, the ASCO Foundation YIA for supporting Nayan this year #asco23

Congratulations Dan! Great to hear

Thrilled to officially launch OurHealth! Help us identify the reasons why South Asian Americans are at increased risk for heart disease, stroke, diabetes, & others. A new virtual & community-based nationwide initiative to build the infrastructure. ourhealthstudy.org

Did someone say there was a new study to understand heart disease risk in South Asians? ourhealthstudy.org 💜

.Kimmie Ng, MD, MPH highlights Count Me In, a new digital platform where young-onset cancer patients can gather and aggregate their experiences with the goal of accelerating research #GI24

Dr. Wagle (Nikhil Wagle, MD (he/him)) offered insights on how to maximize the impact of translational research and wondered what we need to make translational data sets more impactful. Join the Genomic Approaches Toward Precision Cancer Medicine Symposium here⬇️ dfci-ccg.github.io/symposium/inde…

New study in Nature Communications👉Exemestane plus everolimus and palbociclib in #MetastaticBreastCancer: Clinical response & genomic/transcriptomic determinants of resistance in a phase I/II trial Ann Partridge MD, MPH Nancy Lin, MD Sara Tolaney Nikhil Wagle, MD (he/him) Nabihah Tayob 👉pubmed.ncbi.nlm.nih.gov/38503755/

Starting a stimulating session about industry and academia in neuroimmunology led by Skip Virgin, Nikhil Wagle, MD (he/him), Frank Gentile, and Vineeta Agarwala #ReThinkNeuroimmunology

idea now happening. standing platform to accelerate ctDNA based clinical trials. Proud to be leading this! Mass General Cancer Center Science for America along side @ArielleMedford Scott Kopetz Van Morris, MD Arvind Dasari, MD, MS Neil H. Segal MD PhD Meredith Pelster Nikhil Wagle, MD (he/him) & others! nature.com/articles/s4156…

A huge day for spatial omics of cancer, tracing the precise origin and evolution of 20 types of cancer, many in 3D, in ~2,000 individuals, with 12 publications nature Nature Cancer Nature Medicine Nature Methods Communications Biology Collection nature.com/immersive/d428…

Because ONE spatial profiling technology is not enough! New paper by Nikhil Wagle, MD (he/him) in Nature Medicine A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features nature.com/articles/s4159… Dissociated single

New research recently published in Nature Medicine showcases a multi-modal single-cell and spatial expression map of #MetastaticBreastCancer biopsies across clinicopathological features. Check it out here: 🔓pubmed.ncbi.nlm.nih.gov/39478111/ ✍️Daniel Abravanel, MD/PhD Daniel Goodwin Mor Nitzan

After turkey and all the trimmings, have a gander at this editorial on IO in TNBC. Immunotherapy for Early-Stage Triple-Negative Breast Cancer | New England Journal of Medicine nejm.org/doi/full/10.10…

Thanks BioCentury for this opportunity to discuss biomarkers, translational research, and our new Translational Medicine organization at Genentech / Roche

It has been unclear why cancer patients with CH have worse outcomes. Our work published NEJM uncovers that Tumor infiltrating CH (TI-CH) has a direct role in immune remodelling of the TME with implications for tumor progression & treatment response. Memorial Sloan Kettering Cancer Center The Crick

In patients with PIK3CA-mutated advanced breast cancer, inavolisib added to palbociclib–fulvestrant led to a significant overall survival benefit, with a higher incidence of certain toxic effects than placebo. Full INAVO120 trial results: nej.md/3Zje7Vt #ASCO25 | ASCO